Hari Deshpande

Hari Deshpande is an Associate Professor of Medicine in the Section of Medical Oncology at Yale School of Medicine. He specializes in treating sarcomas, thyroid cancers, and cancers of unknown primary. As Clinical Research Team Leader for Sarcoma and Director of the Medical Oncology Inpatient Consult Service, he focuses on advancing clinical trials and multidisciplinary care. Dr. Deshpande holds leadership roles in the Sarcoma Program and collaborates with surgical oncologists, radiologists, and pathologists to improve treatment options for rare cancers like desmoid tumors and liposarcoma.

Education: MD from Leeds University (1991), BS from Leeds University (1988), followed by residency and fellowship training at Albert Einstein College of Medicine, Montefiore Medical Center, and other institutions.

Research Interests: Dr. Deshpande’s work centers on sarcoma biology, novel therapeutic approaches in thyroid cancer, and optimizing clinical trial designs for rare malignancies. His research emphasizes translational studies and collaboration across disciplines to address treatment challenges in rare tumors. Recent efforts include Phase II trials for dedifferentiated liposarcoma and medullary thyroid carcinoma.

Publications Trends: His articles focus on clinical trials for rare cancers, treatment outcomes, and adverse event management. Key areas include sorafenib for desmoid tumors, trametinib for epithelioid hemangioendothelioma, and regorafenib for thyroid cancers. He also addresses quality-of-care topics like consult service efficacy and post-discharge follow-up.

Scientific Awards: He has received multiple David S Fischer Teaching Awards (2022, 2018, 2011), a Compassionate Caregiver Award (2015), and the Davidoff Teaching Award (1995).

Advising & Grants: While no students are listed, his grants support sarcoma and thyroid cancer research. He leads clinical trials at Yale Cancer Center and collaborates with industry partners like Blueprint Medicines and Exelixis.

Labs/Teams: Active in the Sarcoma Disease Aligned Research Team (DART) and works with multidisciplinary tumor boards at Smilow Cancer Hospital to advance personalized treatment strategies.